MARKETING WITHDRAWL
July 1st, 2002
BY KEITH NUTHALL
THE EUROPEAN Agency for the Evaluation of Medicinal Products has confirmed that the European marketing authorisation to Chiron SpA for Triacelluvax, (a combined diptheria, tetanus and acellular pertussis vaccine), has been withdrawn. The drug was only marketed in Italy and Chiron decided to cease selling the drug, as alternatives are available across Europe.
THE EUROPEAN Agency for the Evaluation of Medicinal Products has confirmed that the European marketing authorisation to Chiron SpA for Triacelluvax, (a combined diptheria, tetanus and acellular pertussis vaccine), has been withdrawn. The drug was only marketed in Italy and Chiron decided to cease selling the drug, as alternatives are available across Europe.
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.